Antibody boost may help infants suppress HIV faster

NCT ID NCT07655141

Not yet recruiting Disease control Sponsor: Hospital Universitario 12 de Octubre Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This trial tests whether adding two lab-made antibodies (ePGT121v1-LS and VRC07-523-LS) to standard antiretroviral therapy can help infants living with HIV achieve viral suppression. Infants up to one year old in Mozambique and Cameroon receive four injections of the antibodies or a placebo over 48 weeks. Researchers monitor safety, how the body processes the antibodies, and whether the combination leads to faster or more sustained viral suppression compared to standard treatment alone.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: broadly neutralizing antibodies (ePGT121v1-LS and VRC07-523-LS)
What this could lead to: If successful, this approach could help infants with HIV achieve viral suppression more quickly and reliably, potentially reducing long-term health complications.
What could go wrong: This is an early-phase trial with a small number of participants, so results may not apply to all infants. The antibodies are given as injections, which may cause side effects or discomfort.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HIV-1-INFECTION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

HIV infectious disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HIV-1-INFECTION

More trials for these conditions

Other studies related to the condition(s) this trial covers.